For research use only. Not for therapeutic Use.
Barecetamab（Cat No.:I042163）is an investigational monoclonal antibody that targets the protein CD40, a co-stimulatory receptor found on immune cells, including B-cells and dendritic cells. CD40 is involved in activating immune responses, particularly in the context of inflammation and tumor immunity. By blocking CD40, barecetamab aims to modulate the immune system to enhance anti-tumor activity and improve immune responses. It is being studied in clinical trials for its potential to treat various cancers, including solid tumors, with the goal of improving patient outcomes through immune system activation and tumor suppression.
| CAS Number | 2275727-74-5 |
| Purity | ≥95% |
